⁃ Histologically confirmed NSCLC cancer which cannot be treated with curative intent with available therapies and is refractory to or progressing after anti-PD(L)1 immunotherapy or immunotherapies.

⁃ At least one tumor lesion (\>15 mm or bigger) must be available for biopsy that in the opinion of the investigator, is accessible to repeated biopsies without major safety concerns.

⁃ The patient must have disease evaluable per RECIST 1.1

⁃ Have adequate organ function as defined in the following values below. Specimens must be collected within 10 days prior to the start of study treatment.

⁃ Hematological laboratory values

• Absolute neutrophil count (ANC): ≥1500/µL

• Platelets: ≥ 100 000/µL

• Hemoglobin: ≥9.0 g/dL or ≥5.6 mmol/L. Criteria must be met without packed red blood cell (pRBC) transfusion within the prior 2 weeks. Participants can be on stable dose of erythropoietin (≥ approximately 3 months.

• Leukocytes (WBC) \> 3.0

⁃ Renal laboratory values

• GFR: \>45 ml/min (Cockcroft-Gault formula).

• Hepatic laboratory values

• Total bilirubin: ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total bilirubin levels \>1.5 × ULN (excluding patients with Gilbert's disease)

• AST (SGOT) and ALT (SGPT): ≤2.5 × ULN (≤5 × ULN for participants with liver metastases)

⁃ Patients must be willing to use adequate forms of contraception from screening, during the trial, and for a minimum of 120 days after end of treatment.

⁃ ECOG/WHO performance score of 0-1 at screening.

⁃ Life expectancy longer than 3 months.